leadf
logo-loader
viewCo-Diagnostics

Co-Diagnostics says coronavirus detection test authorized for use in Australia

The country joins the US, India, Mexico, European Community countries and others in allowing the sale and use of the in vitro diagnostic test

Sydney skyline
Co-Diagnostics’ Logix Smart test has earned emergency use authorization from the US Food and Drug Administration and a CE Mark from European regulators

Co-Diagnostics Inc (NASDAQ:CODX) announced Friday that its Logix Smart coronavirus (COVID-19) detection test has been authorized for use in Australia. 

The company’s distributor in the country has received a Register of Therapeutic Goods certificate from the Australian government. The country joins the US, India, Mexico, European Community countries and others in allowing the sale and use of the in vitro diagnostic test. 

The move comes on the heels of a coronavirus outbreak in Melbourne, the company said, which prompted the state of Victoria to declare a state of disaster. 

READ: Co-Diagnostics technology to be used in FDA-authorized self-collected COVID-19 saliva test

"Co-Diagnostics recognizes the importance of accurate, high-throughput testing in combating surges of coronavirus infections, and we are gratified that our test is being used to help people in so many countries to safely navigate this ongoing pandemic, now also including Australia,” CEO Dwight Egan said in a statement.

Co-Diagnostics’ Logix Smart test has earned emergency use authorization from the US Food and Drug Administration and a CE Mark from European regulators. It is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19.

The company’s Logix Smart COVID-19 test’s high accuracy has been independently validated by PathWest Laboratories in Australia, the Indian National Institute of Pathology, and the Mexican Department of Epidemiology.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Co-Diagnostics

Price: 14.82 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $416.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read